Dose‐adjusted EPOCH and rituximab (DA‐EPOCH‐R) in older patients with high‐risk aggressive diffuse large B‐cell lymphoma: A real‐life multicenter study by the Croatian Cooperative Group for Hematologic diseases (KroHem)
Sign Up to like & getrecommendations! Published in 2023 at "European Journal of Haematology"
DOI: 10.1111/ejh.13957
Abstract: Dose‐adjusted EPOCH and rituximab (DA‐EPOCH‐R) is a regimen used for the treatment of high‐risk diffuse large B‐cell lymphoma (DLBCL) designed to overcome resistance to standard R‐CHOP by combining prolonged exposure of lymphoma cells to cytotoxic… read more here.
Keywords: lymphoma; high risk; rituximab epoch; dose adjusted ... See more keywords